 Matthew Parker
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Artery Disease | 6 | 2015 | 248 | 2.080 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 7 | 2016 | 135 | 2.040 |
Why?
| | Myocardial Perfusion Imaging | 8 | 2016 | 15 | 2.000 |
Why?
| | Image Enhancement | 2 | 2014 | 115 | 1.080 |
Why?
| | Exercise Test | 4 | 2015 | 158 | 0.870 |
Why?
| | Exercise | 2 | 2012 | 518 | 0.730 |
Why?
| | Mesalamine | 1 | 2015 | 2 | 0.680 |
Why?
| | Myocarditis | 1 | 2015 | 15 | 0.670 |
Why?
| | Chest Pain | 1 | 2015 | 36 | 0.660 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2015 | 3 | 0.660 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 49 | 0.660 |
Why?
| | Heart Valve Diseases | 2 | 2015 | 34 | 0.650 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2015 | 43 | 0.650 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 83 | 0.630 |
Why?
| | Artifacts | 1 | 2015 | 71 | 0.630 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 56 | 0.620 |
Why?
| | 3-Iodobenzylguanidine | 1 | 2014 | 3 | 0.620 |
Why?
| | Sympathetic Nervous System | 1 | 2014 | 21 | 0.620 |
Why?
| | Radiation Protection | 1 | 2014 | 19 | 0.620 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 152 | 0.600 |
Why?
| | Purines | 1 | 2012 | 26 | 0.560 |
Why?
| | Pyrazoles | 1 | 2012 | 43 | 0.550 |
Why?
| | Heart | 1 | 2014 | 211 | 0.540 |
Why?
| | Athletes | 1 | 2012 | 8 | 0.530 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 102 | 0.520 |
Why?
| | Exercise Therapy | 1 | 2011 | 37 | 0.490 |
Why?
| | Mitral Valve Insufficiency | 1 | 2010 | 31 | 0.470 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 43 | 0.470 |
Why?
| | Aortic Valve Insufficiency | 1 | 2010 | 28 | 0.470 |
Why?
| | Hospitalization | 1 | 2014 | 637 | 0.450 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 979 | 0.450 |
Why?
| | Heart Failure | 1 | 2014 | 443 | 0.440 |
Why?
| | Neurons | 1 | 2014 | 620 | 0.430 |
Why?
| | Myocardial Infarction | 1 | 2014 | 728 | 0.410 |
Why?
| | Humans | 22 | 2017 | 34160 | 0.380 |
Why?
| | Risk Assessment | 4 | 2015 | 1081 | 0.340 |
Why?
| | Registries | 2 | 2017 | 461 | 0.290 |
Why?
| | Reproducibility of Results | 4 | 2015 | 977 | 0.280 |
Why?
| | Male | 12 | 2016 | 17242 | 0.270 |
Why?
| | Female | 11 | 2015 | 18881 | 0.240 |
Why?
| | Risk Factors | 5 | 2015 | 3030 | 0.220 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 697 | 0.210 |
Why?
| | Middle Aged | 8 | 2016 | 9874 | 0.210 |
Why?
| | Acetanilides | 2 | 2014 | 2 | 0.190 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2016 | 9 | 0.180 |
Why?
| | Inservice Training | 1 | 2017 | 59 | 0.180 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 780 | 0.180 |
Why?
| | Coronary Circulation | 1 | 2016 | 68 | 0.180 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 637 | 0.170 |
Why?
| | Piperazines | 2 | 2014 | 103 | 0.170 |
Why?
| | Viridans Streptococci | 1 | 2015 | 5 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2015 | 6 | 0.170 |
Why?
| | Vascular Fistula | 1 | 2015 | 4 | 0.170 |
Why?
| | Shock | 1 | 2015 | 23 | 0.170 |
Why?
| | Nausea | 1 | 2015 | 22 | 0.170 |
Why?
| | Endocarditis, Bacterial | 1 | 2015 | 23 | 0.170 |
Why?
| | Prognosis | 3 | 2015 | 937 | 0.170 |
Why?
| | Mitral Valve | 1 | 2015 | 31 | 0.170 |
Why?
| | Calcinosis | 1 | 2015 | 51 | 0.170 |
Why?
| | Triage | 1 | 2015 | 43 | 0.170 |
Why?
| | Vomiting | 1 | 2015 | 30 | 0.170 |
Why?
| | Streptococcal Infections | 1 | 2015 | 64 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2015 | 56 | 0.160 |
Why?
| | Dyspnea | 1 | 2015 | 49 | 0.160 |
Why?
| | Electric Countershock | 1 | 2014 | 28 | 0.150 |
Why?
| | Heart Diseases | 1 | 2015 | 141 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2015 | 1543 | 0.150 |
Why?
| | Echocardiography | 2 | 2016 | 199 | 0.150 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 158 | 0.150 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 123 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2014 | 48 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2015 | 97 | 0.150 |
Why?
| | Drug Costs | 1 | 2014 | 43 | 0.150 |
Why?
| | Treatment Outcome | 3 | 2015 | 2667 | 0.150 |
Why?
| | Radiation Dosage | 1 | 2014 | 86 | 0.150 |
Why?
| | Health Status Indicators | 1 | 2014 | 68 | 0.150 |
Why?
| | Proportional Hazards Models | 2 | 2013 | 468 | 0.140 |
Why?
| | Vasodilator Agents | 1 | 2012 | 49 | 0.140 |
Why?
| | Length of Stay | 1 | 2014 | 400 | 0.130 |
Why?
| | Databases, Factual | 1 | 2014 | 400 | 0.130 |
Why?
| | Sex Factors | 2 | 2012 | 660 | 0.130 |
Why?
| | Coronary Angiography | 1 | 2012 | 159 | 0.130 |
Why?
| | Exercise Tolerance | 1 | 2012 | 34 | 0.130 |
Why?
| | Physical Endurance | 1 | 2012 | 36 | 0.130 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 34 | 0.130 |
Why?
| | Coronary Disease | 1 | 2013 | 359 | 0.120 |
Why?
| | Morbidity | 1 | 2011 | 49 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2015 | 2864 | 0.120 |
Why?
| | Quality of Life | 1 | 2014 | 437 | 0.120 |
Why?
| | Confidence Intervals | 1 | 2010 | 244 | 0.110 |
Why?
| | Adult | 4 | 2015 | 9698 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 388 | 0.110 |
Why?
| | Stroke Volume | 1 | 2010 | 192 | 0.110 |
Why?
| | Disease Progression | 1 | 2011 | 479 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 447 | 0.110 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 560 | 0.110 |
Why?
| | United States | 3 | 2014 | 4021 | 0.100 |
Why?
| | Aged | 4 | 2014 | 7641 | 0.100 |
Why?
| | Age Factors | 1 | 2010 | 1100 | 0.090 |
Why?
| | Echocardiography, Transesophageal | 2 | 2015 | 47 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2014 | 489 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2014 | 279 | 0.070 |
Why?
| | Chronic Disease | 2 | 2014 | 536 | 0.060 |
Why?
| | Time Factors | 2 | 2015 | 2605 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2015 | 10 | 0.040 |
Why?
| | New York | 1 | 2015 | 66 | 0.040 |
Why?
| | Debridement | 1 | 2015 | 18 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2015 | 31 | 0.040 |
Why?
| | Connecticut | 1 | 2015 | 75 | 0.040 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 34 | 0.040 |
Why?
| | Observer Variation | 1 | 2015 | 147 | 0.040 |
Why?
| | Electrocardiography | 1 | 2016 | 292 | 0.040 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2015 | 45 | 0.040 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2015 | 86 | 0.040 |
Why?
| | Hemodynamics | 1 | 2015 | 170 | 0.040 |
Why?
| | Cause of Death | 1 | 2015 | 115 | 0.040 |
Why?
| | Placebos | 1 | 2014 | 66 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 19 | 0.040 |
Why?
| | Survival Rate | 1 | 2015 | 489 | 0.040 |
Why?
| | Patient Selection | 1 | 2015 | 309 | 0.040 |
Why?
| | Anticoagulants | 1 | 2015 | 217 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 179 | 0.040 |
Why?
| | Prevalence | 1 | 2015 | 795 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2012 | 48 | 0.030 |
Why?
| | Technetium | 1 | 2012 | 51 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2012 | 60 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2013 | 129 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2012 | 7 | 0.030 |
Why?
| | ROC Curve | 1 | 2012 | 145 | 0.030 |
Why?
| | Clinical Competence | 1 | 2015 | 386 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 694 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 382 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2012 | 531 | 0.030 |
Why?
| | Cohort Studies | 1 | 2014 | 1417 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 853 | 0.030 |
Why?
| | Research Design | 1 | 2012 | 393 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2013 | 2553 | 0.020 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|